Pancreatic Cancer Research

ResearcherQingdao UniversityActive in the last 2 years

Hao Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6881-9977; OpenAlex author ID A5100446035. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 13

  1. Sequential nimotuzumab plus gemcitabine and nab-paclitaxel chemotherapy followed by irreversible electroporation in advanced pancreatic ductal adenocarcinoma: … Co-author DOI 10.20892/j.issn.2095-3941.2025.0848↗
  2. Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma. Co-author DOI 10.3389/fimmu.2026.1715761↗
  3. Combination of imaging features on pancreatic CT for predicting early recurrence after upfront pancreatoduodenectomy of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejro.2025.100672↗
  4. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Co-author DOI 10.1126/sciadv.adk1827↗
  5. A CT Radiomics-Based Risk Score for Preoperative Estimation of Intraoperative Superior Mesenteric-Portal Vein Involvement in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-022-12664-0↗
  6. A Single-Cell Atlas of Tumor-Infiltrating Immune Cells in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.mcpro.2022.100258↗
  7. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled… Co-author DOI 10.1016/j.prro.2022.02.009↗
  8. A four oxidative stress gene prognostic model and integrated immunity-analysis in pancreatic adenocarcinoma. Co-author DOI 10.3389/fonc.2022.1015042↗
  9. Analysis of radiotherapy impact on survival in resected stage I/II pancreatic cancer patients: a population-based study Co-author DOI 10.21203/rs.3.rs-126795/v2↗
  10. Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1042/bsr20201190↗
  11. An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocar… Co-author DOI 10.18632/oncotarget.27586↗
  12. Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma. First author DOI 10.18632/oncotarget.12834↗
  13. Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. Co-author DOI 10.1016/j.prro.2011.06.009↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel A. Laheru · 5 shared papers, 2012–2026 · strength 0.63
  2. Lei Zheng · 4 shared papers, 2012–2026 · strength 0.55
  3. Amol Kumar Narang · 4 shared papers, 2012–2026 · strength 0.55
  4. Elizabeth M. Jaffee · 4 shared papers, 2012–2026 · strength 0.50
  5. Dung Thi Le · 4 shared papers, 2012–2026 · strength 0.48
  6. Fang‐Ming Chen · 2 shared papers, 2023–2025 · strength 0.46
  7. Yongping Zhou · 2 shared papers, 2023–2025 · strength 0.46
  8. Ana De Jesus‐Acosta · 2 shared papers, 2020–2026 · strength 0.32
  9. Joseph M. Herman · 3 shared papers, 2012–2024 · strength 0.31
  10. Jin Peng He · 2 shared papers, 2022–2024 · strength 0.29
  11. Gui-Xue Dai · 1 shared paper, 2025 · strength 0.27
  12. Shuanglin Zhang · 1 shared paper, 2025 · strength 0.27
  13. Yong Xu · 1 shared paper, 2026 · strength 0.26
  14. Yi Liu · 1 shared paper, 2026 · strength 0.26
  15. Tongguo Si · 1 shared paper, 2026 · strength 0.26
  16. Chuntao Gao · 1 shared paper, 2026 · strength 0.26
  17. Jihui Hao · 1 shared paper, 2026 · strength 0.26
  18. Elizabeth Thompson · 1 shared paper, 2026 · strength 0.24
  19. Arielle Rose Urman · 1 shared paper, 2026 · strength 0.24
  20. Richard Andrew Burkhart · 1 shared paper, 2026 · strength 0.24
  21. Yong Yan · 1 shared paper, 2023 · strength 0.19
  22. Dong Han · 1 shared paper, 2021 · strength 0.17
  23. Qi Fu · 1 shared paper, 2021 · strength 0.17
  24. Timothy Michael Pawlik · 2 shared papers, 2012–2022 · strength 0.16
  25. Robert A. Anders · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.